视黄基硬脂酸酯 | 631-87-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 视黄基硬脂酸酯
• 中文别名: 15-羟基-十八烷
• 英文名称: retinyl stearate
• 英文别名: 9-Stearoyloxy-3.7-dimethyl-1t-(2.2.6-trimethyl-cyclohexen-(6)-yl)-nonatetraen-(1.3t.5t.7t)；O-Stearoyl-[7t.9t.11t.13t]retinol；O-Stearoyl-all-trans-retinol；All-trans-retinyl stearate；[(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] octadecanoate
• CAS: 631-87-8
• 化学式: C₃₈H₆₄O₂
• 分子量: 552.925
• InChiKey: YNGACJMSLZMZOX-FPFNAQAWSA-N

物化性质

• 溶解度：
  氯仿（微溶）、己烷（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  14.7
• 重原子数：
  40
• 可旋转键数：
  23
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  维生素 A 醋酸酯 、 硬脂酸 在 novozyme 435 作用下， 以 甲苯 为溶剂， 反应 20.0h， 生成 视黄基硬脂酸酯
  参考文献：
  名称：

  An LC/MS/MS method for stable isotope dilution studies of β-carotene bioavailability, bioconversion, and vitamin A status in humans

  摘要：

  Isotope dilution is currently the most accurate technique in humans to determine vitamin A status and bioavailability/bioconversion of provitamin A carotenoids such as beta-carotene. However, limits of MS detection, coupled with extensive isolation procedures, have hindered investigations of physiologically-relevant doses of stable isotopes in large intervention trials. Here, a sensitive liquid chromatography-tandem mass spectrometry (LC/MS/MS) analytical method was developed to study the plasma response from coadministered oral doses of 2 mg [C-13(10)]beta-carotene and 1 mg [C-13(10)]retinyl acetate in human subjects over a 2 week period. A reverse phase C-18 column and binary mobile phase solvent system separated beta-carotene, retinol, retinyl acetate, retinyl linoleate, retinyl palmitate/retinyl oleate, and retinyl stearate within a 7 min run time. Selected reaction monitoring of analytes was performed under atmospheric pressure chemical ionization in positive mode at m/z 537 -> 321 and m/z 269 -> 93 for respective [C-12]beta-carotene and [C-12]retinoids; m/z 547 -> 330 and m/z 274 -> 98 for [C-13(10)]beta-carotene and [C-13(5)] cleavage products; and m/z 279 -> 100 for metabolites of [C-13(10)]retinyl acetate. A single one-phase solvent extraction, with no saponification or purification steps, left retinyl esters intact for determination of intestinally-derived retinol in chylomicrons versus retinol from the liver bound to retinol binding protein. Coadministration of [C-13(10)]retinyl acetate with [C-13(10)]beta-carotene not only acts as a reference dose for inter-individual variations in absorption and chylomicron clearance rates, but also allows for simultaneous determination of an individual's vitamin A status.

  DOI：

  10.1194/jlr.d040204

文献信息

• Mitochondria-targeted antioxidants
  申请人：Ghosal Shibnath

  公开号：US20080031862A1

  公开（公告）日：2008-02-07

  The present invention relates to a pharmaceutical or veterinary or nutritional or personal care composition comprising coenzyme Q 10 (CoQ 10 ), reduced CoQ 10 , or mixtures thereof and oxygenated dibenzo-α-pyrone or an amino acyl ester thereof. The composition of the present invention is able to support and/or provide therapy to individuals at risk and/or under treatment for dysfunctions of energy metabolism, and specifically, for mitochondrial diseases.

  本发明涉及一种包含辅酶Q10（CoQ10）、还原辅酶Q10或二苯并α-吡喃氧化物或其氨基酰酯的药用、兽医、营养或个人护理组合物。本发明的组合物能够支持和/或为处于能量代谢功能障碍风险和/或治疗中的个体提供治疗，特别是用于线粒体疾病。
• [EN] PFKFB3 INHIBITORS AND THEIR USES<br/>[FR] INHIBITEURS DE PFKFB3 ET LEURS UTILISATIONS
  申请人：GERO DISCOVERY LLC

  公开号：WO2020080979A1

  公开（公告）日：2020-04-23

  This disclosure relates to new phthalimide and isoindolinone derivatives and other PFKFB3 inhibitors for use in the treatment of diseases. The invention further relates to pharmaceutical compositions containing such PFKFB3 inhibitors, methods of preparation thereof, methods for their use as therapeutic agents, and methods of preparation of a medicament for use in therapy, as well as kits and other inventiions comprising such PFKFB3 inhibitors. These PFKFB3 inhibitors are useful for the treatment and prophylaxis of cancer, neurodegenerative diseases, autoimmune diseases, inflammatory disorders, multiple sclerosis, metabolic diseases, inhibition of angiogenesis and other diseases and conditions, where the modulation of PFKFB3 and/or PFKFB4 has beneficial effect as well as neuroprotection.

  这项披露涉及新的邻苯二甲酰亚胺和异吲哚酮衍生物以及其他PFKFB3抑制剂，用于治疗疾病。该发明还涉及含有此类PFKFB3抑制剂的药物组合物，其制备方法，作为治疗剂的使用方法，以及用于治疗的药物的制备方法，以及包含此类PFKFB3抑制剂的工具包和其他发明。这些PFKFB3抑制剂对于治疗和预防癌症、神经退行性疾病、自身免疫疾病、炎症性疾病、多发性硬化症、代谢性疾病、抑制血管生成以及其他疾病和情况具有用途，在这些情况下，PFKFB3和/或PFKFB4的调节具有益处，以及神经保护作用。
• Chroman derivatives as lipoxygenase inhibitors
  申请人：Zhang Wei

  公开号：US20060193797A1

  公开（公告）日：2006-08-31

  The present invention is concerned with certain novel derivatives of Formula I: wherein X and R 1 to R 10 are as described in the specification, and where either R 5 is OH, —NR d OR a or —NR d —NR b R c , or R 7 is —NR d OR a or —NR d —NR b R c , or C═R 7 R 8 is C═NOR a or C═N—NR b R c , which may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenases. They may also be useful in the manufacture of skin care and/or pharmaceutical compositions for the treatment of lipoxygenase mediated disorders.

  本发明涉及Formula I的某些新颖衍生物：其中X和R1至R10如规范中所述，其中R5为OH，—NRdORa或—NRd—NRbRc之一，或R7为—NRdORa或—NRd—NRbRc之一，或C═R7R8为C═NORa或C═N—NRbRc，这些可能在制造用于治疗通过脂氧合酶介导的疾病的药物组合物中有用。它们还可能在制造用于治疗脂氧合酶介导疾病的皮肤护理和/或药用组合物中有用。
• Über die Ester und Äther des synthetischen Vitamins A
  作者：O. Isler、A. Ronco、W. Guex、N. C. Hindley、W. Huber、K. Dialer、M. Kofler

  DOI：10.1002/hlca.19490320218

  日期：1949.3.15

  und Äther des Vitamins A wurden nach dem von uns früher beschriebenen Aufbauprinzip dargestellt. Die Schmelzpunkte der synthetischen Krystallisate stimmen mit den bekannten Schmelzpunkten der entsprechenden Vitamin-A-Präparate aus Leberölen überein. Die Wirksamkeit der Ester (Standard-β-Carotin) berechnet auf 1 g Vitamin-A-Alkohol betrug 3,3±0,6 Millionen i. E. Der Methyläther besitzt annähernd die

  Einige reine酯和其他维生素A wurden nach dem von unsfrüherbeschriebenen Aufbauprinzip dargestellt。合成维生素K晶体的刺激物，维生素A的Leberölenüberein。Der Wirksamkeit der Ester（Standard-β-Carotin）berechnet auf 1 g维生素A-酒精戒酒3,3±0.6百万富翁i。E. DerMethyläther致辞，并与德国和德国的Butylätherdeutlich geringere Wirksamkeit进行了对谈。DerPhenyläthervom Smp。90–91°ist wenig wirksam。325-328毫米̈磨牙模头 50,000摩尔磨模耗材价格-Messung gab ebenfalls gleiche Werte。系统的摩尔分数提高了16
• METHODS FOR PHOTOSTABILIZING INGREDIENTS WITHIN COSMETICS, PERSONAL CARE AND HOUSEHOLD PRODUCTS AND COMPOSITIONS OBTAINED THEREFROM
  申请人：Chaudhuri Ratan K.

  公开号：US20080131381A1

  公开（公告）日：2008-06-05

  The present invention relates to methods and compositions for using photostabilizer compounds for stabilizing formulation ingredients, like flavors, fragrances, colors, antioxidants, polymers, within cosmetics, personal care and household products, against degradation from sun light, heat and air oxidation resulting in improvement in storage stability, viscosity, and maintenance of color of the formulated products.

  本发明涉及使用光稳定剂化合物的方法和组合物，用于稳定化妆品、个人护理和家庭产品中的配方成分，如香料、香料、颜色、抗氧化剂、聚合物，防止其在阳光、热和空气氧化下降解，从而改善储存稳定性、粘度和配方产品的色彩维护。